WO2007058990A3 - Therapy using cytokine inhibitors - Google Patents

Therapy using cytokine inhibitors Download PDF

Info

Publication number
WO2007058990A3
WO2007058990A3 PCT/US2006/043896 US2006043896W WO2007058990A3 WO 2007058990 A3 WO2007058990 A3 WO 2007058990A3 US 2006043896 W US2006043896 W US 2006043896W WO 2007058990 A3 WO2007058990 A3 WO 2007058990A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
therapy
cytokine inhibitors
autoimmune diseases
cytokine
Prior art date
Application number
PCT/US2006/043896
Other languages
French (fr)
Other versions
WO2007058990A2 (en
Inventor
Nancy Delaet
Christopher Larson
Kent Pryor
Bonnie Hepburn
Robin Allgren
Bernard D King
Original Assignee
Kemia Inc
Nancy Delaet
Christopher Larson
Kent Pryor
Bonnie Hepburn
Robin Allgren
Bernard D King
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia Inc, Nancy Delaet, Christopher Larson, Kent Pryor, Bonnie Hepburn, Robin Allgren, Bernard D King filed Critical Kemia Inc
Publication of WO2007058990A2 publication Critical patent/WO2007058990A2/en
Publication of WO2007058990A3 publication Critical patent/WO2007058990A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

The present invention relates to methods of treating autoimmune diseases, which comprise the administration of a cytokine inhibitor alone or in combination with known therapeutics or treatments. The invention also relates to pharmaceutical compositions and dosing Tegimens. In particular, the invention relates to the use of cytokine inhibitors, optionally in conjunction with other therapies, for the treatment of autoimmune diseases, more particularly pemphigus.
PCT/US2006/043896 2005-11-14 2006-11-13 Therapy using cytokine inhibitors WO2007058990A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73662105P 2005-11-14 2005-11-14
US60/736,621 2005-11-14
US78594306P 2006-03-24 2006-03-24
US60/785,943 2006-03-24

Publications (2)

Publication Number Publication Date
WO2007058990A2 WO2007058990A2 (en) 2007-05-24
WO2007058990A3 true WO2007058990A3 (en) 2007-12-06

Family

ID=38049183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043896 WO2007058990A2 (en) 2005-11-14 2006-11-13 Therapy using cytokine inhibitors

Country Status (1)

Country Link
WO (1) WO2007058990A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522290T3 (en) 2006-02-10 2014-11-14 Summit Corporation Plc Duchenne muscular dystrophy treatment
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
TWI398252B (en) 2006-05-26 2013-06-11 Novartis Ag Pyrrolopyrimidine compounds and their uses
WO2008043031A1 (en) 2006-10-04 2008-04-10 Pharmacopeia, Inc. 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AR063141A1 (en) 2006-10-04 2008-12-30 Pharmacopeia Inc DERIVATIVES OF 2- (BENZIMIDAZOLIL) PURINA 8- REPLACED FOR IMMUNOSUPPRESSION
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
KR20100007956A (en) 2007-05-03 2010-01-22 화이자 리미티드 2-pyridine carboxamide derivatives as sodium channel modulators
RS55735B1 (en) 2007-08-03 2017-07-31 Summit (Oxford) Ltd Drug combinations for the treatment of duchenne muscular dystrophy
JP2011530596A (en) 2008-08-11 2011-12-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ Halofuginone analogs and their use for inhibition of tRNA synthetase
BRPI0917791B1 (en) 2008-08-22 2022-03-22 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors, as well as pharmaceutical composition and combination
UY33227A (en) 2010-02-19 2011-09-30 Novartis Ag PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6
US8815265B2 (en) 2010-06-30 2014-08-26 Avon Products, Inc. Cosmetic use of N-substituted sulfonyloxybenzylamines and related compounds
US10155742B2 (en) 2012-01-13 2018-12-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
US10011566B2 (en) 2015-12-15 2018-07-03 Astrazeneca Ab Compounds
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
US10407446B2 (en) 2016-12-20 2019-09-10 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
EP3638661A1 (en) 2017-06-14 2020-04-22 Astrazeneca AB 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
WO2019126731A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
PL3759109T3 (en) 2018-02-26 2024-03-04 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
EP3801525A4 (en) 2018-06-08 2022-03-23 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase
KR20210012588A (en) * 2019-07-26 2021-02-03 아주대학교산학협력단 Novel Small molecule Compound Inhibiting TLR7 and TLR9 Signaling Pathways and Uses Thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236193A1 (en) * 2001-10-11 2003-12-25 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US20040166111A1 (en) * 2002-10-24 2004-08-26 Zehra Kaymakcalan Low dose methods for treating disorders in which TNFalpha activity is detrimental
US6797267B2 (en) * 1997-11-05 2004-09-28 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US20040198697A1 (en) * 1992-05-01 2004-10-07 Cohen Irun R. Compositions for the regulation of cytokine activity
US20050107399A1 (en) * 2003-09-11 2005-05-19 Kemia, Inc. Cytokine inhibitors
US20050176687A1 (en) * 2001-06-29 2005-08-11 Alain Moussy Use of tyrosine kinase inhibitors for treating autoimmune diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198697A1 (en) * 1992-05-01 2004-10-07 Cohen Irun R. Compositions for the regulation of cytokine activity
US6797267B2 (en) * 1997-11-05 2004-09-28 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US20050176687A1 (en) * 2001-06-29 2005-08-11 Alain Moussy Use of tyrosine kinase inhibitors for treating autoimmune diseases
US20030236193A1 (en) * 2001-10-11 2003-12-25 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US20040166111A1 (en) * 2002-10-24 2004-08-26 Zehra Kaymakcalan Low dose methods for treating disorders in which TNFalpha activity is detrimental
US20050107399A1 (en) * 2003-09-11 2005-05-19 Kemia, Inc. Cytokine inhibitors

Also Published As

Publication number Publication date
WO2007058990A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2007058990A3 (en) Therapy using cytokine inhibitors
WO2007146712A3 (en) Therapy using cytokine inhibitors
WO2006091862A3 (en) Cytokine inhibitors and their use in therapy
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
MX2009002893A (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates.
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
TN2011000200A1 (en) Combination therapy with peptide epoxyketones
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2005099749A3 (en) Methods for controlling angiogenesis and cell proliferation
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2007041388A3 (en) Prevention and treatment of hearing disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 08.09.2008.

122 Ep: pct application non-entry in european phase

Ref document number: 06837388

Country of ref document: EP

Kind code of ref document: A2